Nasdaq · CIK 0001506251
CTXR Citius Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Sep 23, 2025.
Citius Pharmaceuticals, Inc. (CTXR) has 11 SEC Form 4 filings on file from 9 insiders, the latest filed on Sep 23, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Citius Pharmaceuticals, Inc., scored.
Transactions
Every row filed, 18 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 8, 2025 | Leonard L Mazur Chief Executive Officer | DDisposition to issuer Warrant to Purchase Common Stockderivative | -125,490 | - | - | 0 | Sep 23, 2025 |
| Aug 8, 2025 | Leonard L Mazur Chief Executive Officer | AGrant or award Warrant to Purchase Common Stockderivative | +125,490 | - | - | 125,490 | Sep 23, 2025 |
| Aug 8, 2025 | Leonard L Mazur Chief Executive Officer | DDisposition to issuer Warrant to Purchase Common Stockderivative | -89,388 | - | - | 0 | Sep 23, 2025 |
| Aug 8, 2025 | Leonard L Mazur Chief Executive Officer | AGrant or award Warrant to Purchase Common Stockderivative | +89,388 | - | - | 89,388 | Sep 23, 2025 |
| Aug 8, 2025 | Myron Z Holubiak Vice Chairman | DDisposition to issuer Warrant to Purchase Common Stockderivative | -31,373 | - | - | 0 | Aug 12, 2025 |
| Aug 8, 2025 | Myron Z Holubiak Vice Chairman | AGrant or award Warrant to Purchase Common Stockderivative | +31,373 | - | - | 31,373 | Aug 12, 2025 |
| Aug 8, 2025 | Myron Z Holubiak Vice Chairman | DDisposition to issuer Warrant to Purchase Common Stockderivative | -22,344 | - | - | 0 | Aug 12, 2025 |
| Aug 8, 2025 | Myron Z Holubiak Vice Chairman | AGrant or award Warrant to Purchase Common Stockderivative | +22,344 | - | - | 22,344 | Aug 12, 2025 |
| Nov 7, 2024 | Robert Joseph Smith director | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +125,000 | $0.00 | $0 | 125,000 | Nov 12, 2024 |
| Nov 7, 2024 | Myron Czuczman Chief Medical Officer | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +300,000 | $0.00 | $0 | 300,000 | Nov 12, 2024 |
| Nov 7, 2024 | Dennis M McGrath director | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +125,000 | $0.00 | $0 | 125,000 | Nov 12, 2024 |
| Nov 7, 2024 | Suren G Dutia director | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +125,000 | $0.00 | $0 | 125,000 | Nov 12, 2024 |
| Nov 7, 2024 | Carol Webb director | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +125,000 | $0.00 | $0 | 125,000 | Nov 12, 2024 |
| Nov 7, 2024 | Leonard L Mazur Chief Executive Officer | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +600,000 | $0.00 | $0 | 600,000 | Nov 12, 2024 |
| Nov 7, 2024 | Myron Z Holubiak Vice Chairman | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +350,000 | $0.00 | $0 | 350,000 | Nov 12, 2024 |
| Nov 7, 2024 | Eugene Myron Holuka director | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +125,000 | $0.00 | $0 | 125,000 | Nov 12, 2024 |
| Nov 7, 2024 | Jaime Bartushak Chief Financial Officer | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +350,000 | $0.00 | $0 | 350,000 | Nov 12, 2024 |
| Nov 7, 2024 | Myron Z Holubiak Vice Chairman | AGrant or award Stock Option (Right to Buy)derivativeindirect: See footnote | +75,000 | $0.00 | $0 | 75,000 | Nov 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jaime BartushakChief Financial Officer
- Myron CzuczmanChief Medical Officer
- Suren G Dutiadirector
- Myron Z HolubiakVice Chairman
- Eugene Myron Holukadirector
- Dennis M McGrathdirector, cfo, president, officer
- Leonard L MazurChief Executive Officer
- Robert Joseph Smithdirector
- Carol Webbdirector
Questions about CTXR
Answered from the filings on this page, as of the latest one.
Are insiders buying CTXR?
No. In the last 90 days no insider at Citius Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CTXR on the open market?
No open-market trade has been scored at Citius Pharmaceuticals, Inc.. The latest Form 4 on file was filed on Sep 23, 2025 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Citius Pharmaceuticals, Inc.?
9 people have filed a Form 4 at Citius Pharmaceuticals, Inc., among them Jaime Bartushak (Chief Financial Officer), Myron Czuczman (Chief Medical Officer), Suren G Dutia (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.